Cargando…

Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma

AIM: Alterations in circadian rhythms caused by tumor growth are thought to be clinically relevant as they affect the prognosis and treatment response. We aimed to evaluate the chronotherapeutic approach in rats with ovarian cancer receiving cisplatin intravenously (IV) or with hyperthermic intraper...

Descripción completa

Detalles Bibliográficos
Autores principales: Kireeva, Galina, Gubareva, Ekaterina, Maydin, Mikhail, Osetnik, Vladislav, Kruglov, Stepan, Panchenko, Andrey, Dorofeeva, Anastasia, Tyndyk, Margarita, Fedoros, Elena, Anisimov, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163628/
https://www.ncbi.nlm.nih.gov/pubmed/34079283
http://dx.doi.org/10.2147/OTT.S309285
_version_ 1783700945188683776
author Kireeva, Galina
Gubareva, Ekaterina
Maydin, Mikhail
Osetnik, Vladislav
Kruglov, Stepan
Panchenko, Andrey
Dorofeeva, Anastasia
Tyndyk, Margarita
Fedoros, Elena
Anisimov, Vladimir
author_facet Kireeva, Galina
Gubareva, Ekaterina
Maydin, Mikhail
Osetnik, Vladislav
Kruglov, Stepan
Panchenko, Andrey
Dorofeeva, Anastasia
Tyndyk, Margarita
Fedoros, Elena
Anisimov, Vladimir
author_sort Kireeva, Galina
collection PubMed
description AIM: Alterations in circadian rhythms caused by tumor growth are thought to be clinically relevant as they affect the prognosis and treatment response. We aimed to evaluate the chronotherapeutic approach in rats with ovarian cancer receiving cisplatin intravenously (IV) or with hyperthermic intraperitoneal chemoperfusion (HIPEC) and to assess daily variations in tumor and intestinal epithelium proliferation. METHODS: In the pilot study, we used 12 intact rats and 12 rats with transplantable ovarian cancer, which were euthanized at ZT0 (08:00, lights on), ZT6, ZT12 and ZT18. In the main study, we used 45 rats with transplantable ovarian cancer. Animals were randomized into five groups: control, HIPEC with cisplatin at ZT0 (08:00), HIPEC with cisplatin at ZT12 (20:00), IV cisplatin at ZT0 and IV cisplatin at ZT12. We assessed the proliferation rate of tumor and small intestinal epithelium, apoptosis in small intestinal epithelium, and levels of γ-H2AX (DNA damage/repair marker) in kidneys and liver. Survival was calculated in each group. RESULTS: Ascitic ovarian cancer disrupted daily variations in intestinal epithelium proliferation and DNA damage/repair in rats. Ovarian carcinoma exhibited no daily variation in mitotic activity. In animals receiving IV cisplatin, massive cell damage in the renal medulla and cystic changes within renal tubules were observed, unlike in rats receiving HIPEC. Tumor mitotic activity was lower in morning-treated groups. The median survival of rats in the control group was 8.5 days (95% CI 6.0–22.0), in HIPEC at ZT0 40.5 days (95% CI 28.0–47.0, p<0.001) and in HIPEC at ZT12 32.0 days (95% CI 28.0–37.0, p<0.001). CONCLUSION: In a rat model, ovarian tumor growth disrupted daily variations in intestinal epithelium proliferation and caused genotoxic stress in tumor-free tissues. HIPEC with cisplatin at ZT0 had a better efficacy/toxicity profile than HIPEC with cisplatin at ZT12 and IV administration at both time points.
format Online
Article
Text
id pubmed-8163628
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81636282021-06-01 Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma Kireeva, Galina Gubareva, Ekaterina Maydin, Mikhail Osetnik, Vladislav Kruglov, Stepan Panchenko, Andrey Dorofeeva, Anastasia Tyndyk, Margarita Fedoros, Elena Anisimov, Vladimir Onco Targets Ther Original Research AIM: Alterations in circadian rhythms caused by tumor growth are thought to be clinically relevant as they affect the prognosis and treatment response. We aimed to evaluate the chronotherapeutic approach in rats with ovarian cancer receiving cisplatin intravenously (IV) or with hyperthermic intraperitoneal chemoperfusion (HIPEC) and to assess daily variations in tumor and intestinal epithelium proliferation. METHODS: In the pilot study, we used 12 intact rats and 12 rats with transplantable ovarian cancer, which were euthanized at ZT0 (08:00, lights on), ZT6, ZT12 and ZT18. In the main study, we used 45 rats with transplantable ovarian cancer. Animals were randomized into five groups: control, HIPEC with cisplatin at ZT0 (08:00), HIPEC with cisplatin at ZT12 (20:00), IV cisplatin at ZT0 and IV cisplatin at ZT12. We assessed the proliferation rate of tumor and small intestinal epithelium, apoptosis in small intestinal epithelium, and levels of γ-H2AX (DNA damage/repair marker) in kidneys and liver. Survival was calculated in each group. RESULTS: Ascitic ovarian cancer disrupted daily variations in intestinal epithelium proliferation and DNA damage/repair in rats. Ovarian carcinoma exhibited no daily variation in mitotic activity. In animals receiving IV cisplatin, massive cell damage in the renal medulla and cystic changes within renal tubules were observed, unlike in rats receiving HIPEC. Tumor mitotic activity was lower in morning-treated groups. The median survival of rats in the control group was 8.5 days (95% CI 6.0–22.0), in HIPEC at ZT0 40.5 days (95% CI 28.0–47.0, p<0.001) and in HIPEC at ZT12 32.0 days (95% CI 28.0–37.0, p<0.001). CONCLUSION: In a rat model, ovarian tumor growth disrupted daily variations in intestinal epithelium proliferation and caused genotoxic stress in tumor-free tissues. HIPEC with cisplatin at ZT0 had a better efficacy/toxicity profile than HIPEC with cisplatin at ZT12 and IV administration at both time points. Dove 2021-05-24 /pmc/articles/PMC8163628/ /pubmed/34079283 http://dx.doi.org/10.2147/OTT.S309285 Text en © 2021 Kireeva et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kireeva, Galina
Gubareva, Ekaterina
Maydin, Mikhail
Osetnik, Vladislav
Kruglov, Stepan
Panchenko, Andrey
Dorofeeva, Anastasia
Tyndyk, Margarita
Fedoros, Elena
Anisimov, Vladimir
Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
title Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
title_full Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
title_fullStr Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
title_full_unstemmed Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
title_short Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
title_sort efficacy and safety of systemic and locoregional cisplatin chronotherapy in rats with ovarian carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163628/
https://www.ncbi.nlm.nih.gov/pubmed/34079283
http://dx.doi.org/10.2147/OTT.S309285
work_keys_str_mv AT kireevagalina efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT gubarevaekaterina efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT maydinmikhail efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT osetnikvladislav efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT kruglovstepan efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT panchenkoandrey efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT dorofeevaanastasia efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT tyndykmargarita efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT fedoroselena efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma
AT anisimovvladimir efficacyandsafetyofsystemicandlocoregionalcisplatinchronotherapyinratswithovariancarcinoma